JAK-inhibition in Recurrent Classical Hodgkin Lymphoma

NCT02164500 | Completed Phase 2

• 1 other identifier: JeRiCHO
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

The Purpose of this trial is:

• to determine the overall response rate (ORR, complete response \[CR\] + partial response \[PR\]) in patients with relapsed or refractory HL
• to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL

Conditions

Recurrent Classical Hodgkin Lymphoma

Outcome Measures

Primary Outcomes (1)

• overall response rate

  8 weeks

Study Arms (1)

Ruxolitinib

EXPERIMENTAL

Drug: Ruxolitinib

Interventions

Ruxolitinib DRUG

Ruxolitinib

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• relapsed or refractory HL
• ECOG \<= 2,
• no major organ dysfunction
• written informed consent

You may not qualify if:

• history of another primary malignancy ≤ 2 years
• female patients who are pregnant or breast feeding
• patients with a known history of HIV seropositivity
• chronic active hepatitis

Sponsors & Collaborators

• University of Cologne: lead

Study Sites (1)

1st Dept. of Medicine, Cologne University Hospital

Cologne, 50924, Germany

Location

Related Links

• Homepage GHSG

MeSH Terms

Interventions

ruxolitinib

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr.

Study Record Dates

• First Submitted: June 12, 2014
• First Posted: June 16, 2014
• Study Start: October 1, 2015
• Primary Completion: May 17, 2019
• Study Completion: May 17, 2019
• Last Updated: April 6, 2020

Record last verified: 2020-04

Locations

DE (1)